Citius Oncology (NASDAQ:CTOR) Shares Down 2% – What’s Next?

Citius Oncology, Inc. (NASDAQ:CTOR)’s share price was down 2% on Friday . The stock traded as low as $0.7612 and last traded at $0.78. Approximately 48,521 shares changed hands during trading, a decline of 33% from the average daily volume of 71,935 shares. The stock had previously closed at $0.7959.

Citius Oncology Price Performance

The business’s fifty day moving average price is $0.81 and its 200-day moving average price is $0.99. The company has a market capitalization of $72.52 million, a P/E ratio of -1.66 and a beta of 3.41. The company has a current ratio of 0.50, a quick ratio of 0.12 and a debt-to-equity ratio of 0.11.

Citius Oncology (NASDAQ:CTOR) last released its quarterly earnings results on Friday, May 15th. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.26). The business had revenue of $1.67 million during the quarter, compared to analyst estimates of $7.00 million.

Hedge Funds Weigh In On Citius Oncology

Large investors have recently modified their holdings of the company. Citadel Advisors LLC purchased a new position in shares of Citius Oncology during the 3rd quarter valued at about $36,000. Bank of America Corp DE raised its holdings in shares of Citius Oncology by 5,256.9% during the 2nd quarter. Bank of America Corp DE now owns 8,571 shares of the company’s stock valued at $37,000 after buying an additional 8,411 shares in the last quarter. IFP Advisors Inc raised its holdings in shares of Citius Oncology by 49.5% during the 3rd quarter. IFP Advisors Inc now owns 33,215 shares of the company’s stock valued at $67,000 after buying an additional 11,000 shares in the last quarter. OMERS ADMINISTRATION Corp purchased a new position in shares of Citius Oncology during the 4th quarter valued at about $104,000. Finally, Geode Capital Management LLC raised its holdings in shares of Citius Oncology by 31.6% during the 4th quarter. Geode Capital Management LLC now owns 220,047 shares of the company’s stock valued at $220,000 after buying an additional 52,875 shares in the last quarter. 70.52% of the stock is owned by hedge funds and other institutional investors.

Citius Oncology Company Profile

Citius Oncology, Inc is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.